Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment
Background: Several attempts have been made to determine whether interphase fluorescence in situ hybridization (I-FISH) on bone marrow or peripheral blood specimens is a good alternative to conventional cytogenetics (CC) in calculating the residual proportion of Philadelphia (Ph) chromosome-positive...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2004-07, Vol.24 (4), p.2535-2539 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2539 |
|---|---|
| container_issue | 4 |
| container_start_page | 2535 |
| container_title | Anticancer research |
| container_volume | 24 |
| creator | DOUET-GUILBERT, Nathalie MOREL, Frédéric LE CHARPENTIER, Tiffen LE BRIS, Marie-Josée HERRY, Angèle MORICE, Patrick BOURQUARD, Pascal ABGRALL, Jean Francois BERTHOU, Christian DE BRAEKELEER, Marc |
| description | Background: Several attempts have been made to determine whether interphase fluorescence in situ hybridization (I-FISH) on
bone marrow or peripheral blood specimens is a good alternative to conventional cytogenetics (CC) in calculating the residual
proportion of Philadelphia (Ph) chromosome-positive cells during treatment follow-up of patients with chronic myeloid leukemia.
Materials and Methods: Nineteen patients were selected for I-FISH follow-up compared to CC. All samples were also classified
into 4 groups according to the percentage of residual Ph chromosome-positive metaphases analyzed in CC. I-FISH was performed
using the LSI bcr/abl dual ES color probe (Vysis®). Results: A high correlation was observed between the frequency of Ph chromosome-positive
cells, assessed by CC and I-FISH (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66818627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66818627</sourcerecordid><originalsourceid>FETCH-LOGICAL-h267t-aca376a45baa7899b7cd3a26473de89f232140fe40c3d56f3a235b5d0e94a6f93</originalsourceid><addsrcrecordid>eNpN0FFLwzAUBeAiipvTvyB90bdCmjRJ8yjDucFEwflcbttbG02amrSO_XuLTvDpwjkf5-GeRPNUqjSRnJHTaE4oJ4kkhM-iixDeCRFC5ew8mqWcMUJTMo_qTTeg71sIGK82L-u4cT5eOWPcPhn72DXxc6sN1Gj6VkO8bL2zLjiLSe-CHvQX_mSdruLHAxqn63iL4wfaCe88wmCxGy6jswZMwKvjXUSvq_vdcp1snx42y7tt0lIhhwQqYFJAxksAmStVyqpmQEUmWY25aiijaUYazEjFai6aqWO85DVBlYFoFFtEt7-7vXefI4ahsDpUaAx06MZQCJGnuaBygtdHOJYW66L32oI_FH9_mcDNEUCowDQeukqHf07lUrF_rtVv7V57LIIFY6ZZVoCnWZEVlDPOvgFvo3n-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66818627</pqid></control><display><type>article</type><title>Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>DOUET-GUILBERT, Nathalie ; MOREL, Frédéric ; LE CHARPENTIER, Tiffen ; LE BRIS, Marie-Josée ; HERRY, Angèle ; MORICE, Patrick ; BOURQUARD, Pascal ; ABGRALL, Jean Francois ; BERTHOU, Christian ; DE BRAEKELEER, Marc</creator><creatorcontrib>DOUET-GUILBERT, Nathalie ; MOREL, Frédéric ; LE CHARPENTIER, Tiffen ; LE BRIS, Marie-Josée ; HERRY, Angèle ; MORICE, Patrick ; BOURQUARD, Pascal ; ABGRALL, Jean Francois ; BERTHOU, Christian ; DE BRAEKELEER, Marc</creatorcontrib><description>Background: Several attempts have been made to determine whether interphase fluorescence in situ hybridization (I-FISH) on
bone marrow or peripheral blood specimens is a good alternative to conventional cytogenetics (CC) in calculating the residual
proportion of Philadelphia (Ph) chromosome-positive cells during treatment follow-up of patients with chronic myeloid leukemia.
Materials and Methods: Nineteen patients were selected for I-FISH follow-up compared to CC. All samples were also classified
into 4 groups according to the percentage of residual Ph chromosome-positive metaphases analyzed in CC. I-FISH was performed
using the LSI bcr/abl dual ES color probe (Vysis®). Results: A high correlation was observed between the frequency of Ph chromosome-positive
cells, assessed by CC and I-FISH (p<0.001). A high correlation was found between CC and I-FISH for 12 patients, but not for
the remaining 7. Applying the same classification for I-FISH did not show a good relationship between the two techniques (p<0.001).
Conclusion: Dual color I-FISH is a reliable method to monitor the size of the Ph chromosome-positive clone in bone marrow
of treated CML patients. However, it has to be complementary to conventional cytogenetics because it cannot detect the emergence
of other chromosomal abnormalities in Ph chromosome-positive or -negative cells.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 15330210</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Biological and medical sciences ; Bone Marrow Cells - ultrastructure ; False Positive Reactions ; Follow-Up Studies ; Hematologic and hematopoietic diseases ; Humans ; In Situ Hybridization, Fluorescence - methods ; Interphase - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Tumors</subject><ispartof>Anticancer research, 2004-07, Vol.24 (4), p.2535-2539</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15987930$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15330210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DOUET-GUILBERT, Nathalie</creatorcontrib><creatorcontrib>MOREL, Frédéric</creatorcontrib><creatorcontrib>LE CHARPENTIER, Tiffen</creatorcontrib><creatorcontrib>LE BRIS, Marie-Josée</creatorcontrib><creatorcontrib>HERRY, Angèle</creatorcontrib><creatorcontrib>MORICE, Patrick</creatorcontrib><creatorcontrib>BOURQUARD, Pascal</creatorcontrib><creatorcontrib>ABGRALL, Jean Francois</creatorcontrib><creatorcontrib>BERTHOU, Christian</creatorcontrib><creatorcontrib>DE BRAEKELEER, Marc</creatorcontrib><title>Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: Several attempts have been made to determine whether interphase fluorescence in situ hybridization (I-FISH) on
bone marrow or peripheral blood specimens is a good alternative to conventional cytogenetics (CC) in calculating the residual
proportion of Philadelphia (Ph) chromosome-positive cells during treatment follow-up of patients with chronic myeloid leukemia.
Materials and Methods: Nineteen patients were selected for I-FISH follow-up compared to CC. All samples were also classified
into 4 groups according to the percentage of residual Ph chromosome-positive metaphases analyzed in CC. I-FISH was performed
using the LSI bcr/abl dual ES color probe (Vysis®). Results: A high correlation was observed between the frequency of Ph chromosome-positive
cells, assessed by CC and I-FISH (p<0.001). A high correlation was found between CC and I-FISH for 12 patients, but not for
the remaining 7. Applying the same classification for I-FISH did not show a good relationship between the two techniques (p<0.001).
Conclusion: Dual color I-FISH is a reliable method to monitor the size of the Ph chromosome-positive clone in bone marrow
of treated CML patients. However, it has to be complementary to conventional cytogenetics because it cannot detect the emergence
of other chromosomal abnormalities in Ph chromosome-positive or -negative cells.</description><subject>Biological and medical sciences</subject><subject>Bone Marrow Cells - ultrastructure</subject><subject>False Positive Reactions</subject><subject>Follow-Up Studies</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>In Situ Hybridization, Fluorescence - methods</subject><subject>Interphase - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0FFLwzAUBeAiipvTvyB90bdCmjRJ8yjDucFEwflcbttbG02amrSO_XuLTvDpwjkf5-GeRPNUqjSRnJHTaE4oJ4kkhM-iixDeCRFC5ew8mqWcMUJTMo_qTTeg71sIGK82L-u4cT5eOWPcPhn72DXxc6sN1Gj6VkO8bL2zLjiLSe-CHvQX_mSdruLHAxqn63iL4wfaCe88wmCxGy6jswZMwKvjXUSvq_vdcp1snx42y7tt0lIhhwQqYFJAxksAmStVyqpmQEUmWY25aiijaUYazEjFai6aqWO85DVBlYFoFFtEt7-7vXefI4ahsDpUaAx06MZQCJGnuaBygtdHOJYW66L32oI_FH9_mcDNEUCowDQeukqHf07lUrF_rtVv7V57LIIFY6ZZVoCnWZEVlDPOvgFvo3n-</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>DOUET-GUILBERT, Nathalie</creator><creator>MOREL, Frédéric</creator><creator>LE CHARPENTIER, Tiffen</creator><creator>LE BRIS, Marie-Josée</creator><creator>HERRY, Angèle</creator><creator>MORICE, Patrick</creator><creator>BOURQUARD, Pascal</creator><creator>ABGRALL, Jean Francois</creator><creator>BERTHOU, Christian</creator><creator>DE BRAEKELEER, Marc</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment</title><author>DOUET-GUILBERT, Nathalie ; MOREL, Frédéric ; LE CHARPENTIER, Tiffen ; LE BRIS, Marie-Josée ; HERRY, Angèle ; MORICE, Patrick ; BOURQUARD, Pascal ; ABGRALL, Jean Francois ; BERTHOU, Christian ; DE BRAEKELEER, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h267t-aca376a45baa7899b7cd3a26473de89f232140fe40c3d56f3a235b5d0e94a6f93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Bone Marrow Cells - ultrastructure</topic><topic>False Positive Reactions</topic><topic>Follow-Up Studies</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>In Situ Hybridization, Fluorescence - methods</topic><topic>Interphase - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DOUET-GUILBERT, Nathalie</creatorcontrib><creatorcontrib>MOREL, Frédéric</creatorcontrib><creatorcontrib>LE CHARPENTIER, Tiffen</creatorcontrib><creatorcontrib>LE BRIS, Marie-Josée</creatorcontrib><creatorcontrib>HERRY, Angèle</creatorcontrib><creatorcontrib>MORICE, Patrick</creatorcontrib><creatorcontrib>BOURQUARD, Pascal</creatorcontrib><creatorcontrib>ABGRALL, Jean Francois</creatorcontrib><creatorcontrib>BERTHOU, Christian</creatorcontrib><creatorcontrib>DE BRAEKELEER, Marc</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DOUET-GUILBERT, Nathalie</au><au>MOREL, Frédéric</au><au>LE CHARPENTIER, Tiffen</au><au>LE BRIS, Marie-Josée</au><au>HERRY, Angèle</au><au>MORICE, Patrick</au><au>BOURQUARD, Pascal</au><au>ABGRALL, Jean Francois</au><au>BERTHOU, Christian</au><au>DE BRAEKELEER, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>24</volume><issue>4</issue><spage>2535</spage><epage>2539</epage><pages>2535-2539</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: Several attempts have been made to determine whether interphase fluorescence in situ hybridization (I-FISH) on
bone marrow or peripheral blood specimens is a good alternative to conventional cytogenetics (CC) in calculating the residual
proportion of Philadelphia (Ph) chromosome-positive cells during treatment follow-up of patients with chronic myeloid leukemia.
Materials and Methods: Nineteen patients were selected for I-FISH follow-up compared to CC. All samples were also classified
into 4 groups according to the percentage of residual Ph chromosome-positive metaphases analyzed in CC. I-FISH was performed
using the LSI bcr/abl dual ES color probe (Vysis®). Results: A high correlation was observed between the frequency of Ph chromosome-positive
cells, assessed by CC and I-FISH (p<0.001). A high correlation was found between CC and I-FISH for 12 patients, but not for
the remaining 7. Applying the same classification for I-FISH did not show a good relationship between the two techniques (p<0.001).
Conclusion: Dual color I-FISH is a reliable method to monitor the size of the Ph chromosome-positive clone in bone marrow
of treated CML patients. However, it has to be complementary to conventional cytogenetics because it cannot detect the emergence
of other chromosomal abnormalities in Ph chromosome-positive or -negative cells.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>15330210</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2004-07, Vol.24 (4), p.2535-2539 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66818627 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Biological and medical sciences Bone Marrow Cells - ultrastructure False Positive Reactions Follow-Up Studies Hematologic and hematopoietic diseases Humans In Situ Hybridization, Fluorescence - methods Interphase - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Tumors |
| title | Interphase FISH for Follow-up of Philadelphia Chromosome-positive Chronic Myeloid Leukemia Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A22%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interphase%20FISH%20for%20Follow-up%20of%20Philadelphia%20Chromosome-positive%20Chronic%20Myeloid%20Leukemia%20Treatment&rft.jtitle=Anticancer%20research&rft.au=DOUET-GUILBERT,%20Nathalie&rft.date=2004-07-01&rft.volume=24&rft.issue=4&rft.spage=2535&rft.epage=2539&rft.pages=2535-2539&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E66818627%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66818627&rft_id=info:pmid/15330210&rfr_iscdi=true |